Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 Pipeline Review, H1 2018

Summary

Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 pipeline Target constitutes close to 20 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Integrin Beta 3 Pipeline Review, H1 2018, outlays comprehensive information on the Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/integrin-beta-3-platelet-membrane-glycoprotein-iiia-or-cd61-or-itgb3pipeline-review-h1-2018-market-35

Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 Integrin beta3 ?3 or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alphaIIb/beta3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Ophthalmology, Cardiovascular, Dermatology, Gastrointestinal and Infectious Disease which include indications Wet Neovascular / Exudative Macular Degeneration, Glioblastoma Multiforme GBM, Breast Cancer, Diabetic Nephropathy, Diabetic Retinopathy, Melanoma, Arterial Thrombosis, Cardiovascular Disease, Diabetic Macular Edema, Ischemic Cerebral Stroke, Lung Cancer, Malabsorption Syndrome, Metastatic Melanoma, Multiple Myeloma Kahler Disease, Myocardial Infarction, Pancreatic Cancer, Retinal Vein Occlusion, Sepsis and Venous Leg Ulcers Crural ulcer.

Furthermore, this report also reviews key players involved in Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3
The report reviews Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics and enlists all their major and minor projects
The report assesses Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get the Complete Report & TOC @ https://www.24marketreports.com/aerospace-and-defense/integrin-beta-3-platelet-membrane-glycoprotein-iiia-or-cd61-or-itgb3pipeline-review-h1-2018-market-35

Table of content
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 Overview
Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 Companies Involved in Therapeutics Development
Factor Therapeutics Ltd
Merck & Co Inc
SciFluor Life Sciences LLC
SOM Biotech SL
Vascular Pharmaceuticals Inc
VDDI Pharmaceuticals
Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 Drug Profiles
A11 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC301 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C16Y Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cilengitide Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK0429 Dr

If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/integrin-beta-3-platelet-membrane-glycoprotein-iiia-or-cd61-or-itgb3pipeline-review-h1-2018-market-35

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: help@24marketreports.com

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports